Immuron Ltd has released a press release.
Immuron Q3 Sales reach 150% of 1H Sales
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Business Update Presentation
- Immuron Receives FDA Approval for Travelan IND Application
- Immuron completes strategic investment in Ateria Health
- IMC investment in leading gut health biotech Ateria Health
- Immuron Update on IMM-124E SARS-CoV-2 Research
Later from Immuron
- Q3 FY23 Business Update Presentation
- FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic
- Immuron Initiates Recruitment of Travelan Clinical Study
- Immuron FY23 Sales increase 136% on FY22 Sales
- Immuron enrols patients in Travelan clinical study
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron